A Memorandum of Understanding (MOU) was signed between CHO Pharma and MetaTech (AP) Inc. on May 28th, 2020. This is the first-ever collaboration between regenerative medicine and anti-glycan antibody, CHO Pharma and MetaTech will jointly develop the next generation NK technology.

CHO Pharma is a pioneer in glycotechnology, with its patented CHOptimax™ platform, they have successfully selected out a universal glycan that is able to enhance the efficacy of antibody drugs; CHOptimax™ customized antibodies can bind to specific immune cells for precise target selection and purification, which can be further applied as the basis for next generation NK technology. MetaTech on the other hand introduces cellsheet technology exclusively from Japan, and plans to establish a cell production plant in Hsinchu.

This collaboration connects both upstream and downstream companies, they not only aim to develop CAR-NK for immunotherapy but also combine technologies of mesenchymal stem cell selection/purification and cellsheet for stem cell therapies.